The mixed-action delta/mu opioid agonist MMP-2200 does not produce conditioned place preference but does maintain drug self-administration in rats, and induces in vitro markers of tolerance and dependence

Glenn W. Stevenson, Amy Luginbuhl, Catherine Dunbar, Justin Lavigne, Julio Dutra, Phillip Atherton, Brooke Bell, Katherine Cone, Denise Giuvelis, Robin L Polt, John M. Streicher, Edward J. Bilsky

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Abstract Previous work in our laboratories provides preclinical evidence that mixed-action delta/mu receptor glycopeptides have equivalent efficacy for treating pain with reduced side effect profiles compared to widely used mu agonist analgesics such as morphine. This study evaluated the rewarding and reinforcing effects of a lead candidate, mixed-action delta/mu agonist MMP-2200, using a conditioned place preference assay as well as a drug self-administration procedure in rats. In place conditioning studies, rats underwent a 2-week conditioning protocol and were then tested for chamber preference. Rats receiving MMP-2200, at previously determined analgesic doses, could not distinguish between the drug and saline-paired chamber, whereas rats receiving the opioid agonist morphine showed a strong preference for the morphine-paired chamber. In self-administration studies, rats were trained to respond for the high efficacy mu opioid receptor agonist fentanyl on an FR5 schedule of reinforcement. Following complete dose-response determinations for fentanyl, a range of doses of MMP-2200 as well as morphine were tested. Relative to the mu agonist morphine, MMP-2200 maintained a significantly lower number of drug infusions. To begin investigating potential molecular mechanisms for the reduced side effect profile of MMP-2200, we also examined βarrestin2 (βarr2) recruitment and chronic MMP-2200 induced cAMP tolerance and super-activation at the human delta and mu receptors in vitro. MMP-2200 efficaciously recruited βarr2 to both receptors, and induced cAMP tolerance and super-activation equivalent to or greater than morphine at both receptors. The in vivo findings suggest that MMP-2200 may be less reinforcing than morphine but may have some abuse potential. The reduced side effect profile cannot be explained by reduced βarr2 recruitment or reduced cAMP tolerance and superactivation at the monomeric receptors in vitro.

Original languageEnglish (US)
Article number72144
Pages (from-to)49-55
Number of pages7
JournalPharmacology, Biochemistry and Behavior
Volume132
DOIs
StatePublished - 2015

Fingerprint

Self Administration
Opioid Analgesics
Rats
Morphine
Pharmaceutical Preparations
mu Opioid Receptor
delta Opioid Receptor
Fentanyl
Analgesics
Drug infusion
Chemical activation
Cyclic AMP Receptors
Reinforcement Schedule
Glycopeptides
tyrosyl-glycyl-phenylalanyl-leucyl-(O-lactosyl)serinamide
In Vitro Techniques
Assays
Reinforcement
Pain

Keywords

  • Barrestin2
  • cAMP
  • Conditioned place preference
  • Delta opioid receptor (DOR)
  • Drug self-administration
  • Rats

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Pharmacology
  • Toxicology
  • Behavioral Neuroscience
  • Biological Psychiatry

Cite this

The mixed-action delta/mu opioid agonist MMP-2200 does not produce conditioned place preference but does maintain drug self-administration in rats, and induces in vitro markers of tolerance and dependence. / Stevenson, Glenn W.; Luginbuhl, Amy; Dunbar, Catherine; Lavigne, Justin; Dutra, Julio; Atherton, Phillip; Bell, Brooke; Cone, Katherine; Giuvelis, Denise; Polt, Robin L; Streicher, John M.; Bilsky, Edward J.

In: Pharmacology, Biochemistry and Behavior, Vol. 132, 72144, 2015, p. 49-55.

Research output: Contribution to journalArticle

Stevenson, Glenn W. ; Luginbuhl, Amy ; Dunbar, Catherine ; Lavigne, Justin ; Dutra, Julio ; Atherton, Phillip ; Bell, Brooke ; Cone, Katherine ; Giuvelis, Denise ; Polt, Robin L ; Streicher, John M. ; Bilsky, Edward J. / The mixed-action delta/mu opioid agonist MMP-2200 does not produce conditioned place preference but does maintain drug self-administration in rats, and induces in vitro markers of tolerance and dependence. In: Pharmacology, Biochemistry and Behavior. 2015 ; Vol. 132. pp. 49-55.
@article{616c9f6222af4d9b878cd4758ccad1e8,
title = "The mixed-action delta/mu opioid agonist MMP-2200 does not produce conditioned place preference but does maintain drug self-administration in rats, and induces in vitro markers of tolerance and dependence",
abstract = "Abstract Previous work in our laboratories provides preclinical evidence that mixed-action delta/mu receptor glycopeptides have equivalent efficacy for treating pain with reduced side effect profiles compared to widely used mu agonist analgesics such as morphine. This study evaluated the rewarding and reinforcing effects of a lead candidate, mixed-action delta/mu agonist MMP-2200, using a conditioned place preference assay as well as a drug self-administration procedure in rats. In place conditioning studies, rats underwent a 2-week conditioning protocol and were then tested for chamber preference. Rats receiving MMP-2200, at previously determined analgesic doses, could not distinguish between the drug and saline-paired chamber, whereas rats receiving the opioid agonist morphine showed a strong preference for the morphine-paired chamber. In self-administration studies, rats were trained to respond for the high efficacy mu opioid receptor agonist fentanyl on an FR5 schedule of reinforcement. Following complete dose-response determinations for fentanyl, a range of doses of MMP-2200 as well as morphine were tested. Relative to the mu agonist morphine, MMP-2200 maintained a significantly lower number of drug infusions. To begin investigating potential molecular mechanisms for the reduced side effect profile of MMP-2200, we also examined βarrestin2 (βarr2) recruitment and chronic MMP-2200 induced cAMP tolerance and super-activation at the human delta and mu receptors in vitro. MMP-2200 efficaciously recruited βarr2 to both receptors, and induced cAMP tolerance and super-activation equivalent to or greater than morphine at both receptors. The in vivo findings suggest that MMP-2200 may be less reinforcing than morphine but may have some abuse potential. The reduced side effect profile cannot be explained by reduced βarr2 recruitment or reduced cAMP tolerance and superactivation at the monomeric receptors in vitro.",
keywords = "Barrestin2, cAMP, Conditioned place preference, Delta opioid receptor (DOR), Drug self-administration, Rats",
author = "Stevenson, {Glenn W.} and Amy Luginbuhl and Catherine Dunbar and Justin Lavigne and Julio Dutra and Phillip Atherton and Brooke Bell and Katherine Cone and Denise Giuvelis and Polt, {Robin L} and Streicher, {John M.} and Bilsky, {Edward J.}",
year = "2015",
doi = "10.1016/j.pbb.2015.02.022",
language = "English (US)",
volume = "132",
pages = "49--55",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The mixed-action delta/mu opioid agonist MMP-2200 does not produce conditioned place preference but does maintain drug self-administration in rats, and induces in vitro markers of tolerance and dependence

AU - Stevenson, Glenn W.

AU - Luginbuhl, Amy

AU - Dunbar, Catherine

AU - Lavigne, Justin

AU - Dutra, Julio

AU - Atherton, Phillip

AU - Bell, Brooke

AU - Cone, Katherine

AU - Giuvelis, Denise

AU - Polt, Robin L

AU - Streicher, John M.

AU - Bilsky, Edward J.

PY - 2015

Y1 - 2015

N2 - Abstract Previous work in our laboratories provides preclinical evidence that mixed-action delta/mu receptor glycopeptides have equivalent efficacy for treating pain with reduced side effect profiles compared to widely used mu agonist analgesics such as morphine. This study evaluated the rewarding and reinforcing effects of a lead candidate, mixed-action delta/mu agonist MMP-2200, using a conditioned place preference assay as well as a drug self-administration procedure in rats. In place conditioning studies, rats underwent a 2-week conditioning protocol and were then tested for chamber preference. Rats receiving MMP-2200, at previously determined analgesic doses, could not distinguish between the drug and saline-paired chamber, whereas rats receiving the opioid agonist morphine showed a strong preference for the morphine-paired chamber. In self-administration studies, rats were trained to respond for the high efficacy mu opioid receptor agonist fentanyl on an FR5 schedule of reinforcement. Following complete dose-response determinations for fentanyl, a range of doses of MMP-2200 as well as morphine were tested. Relative to the mu agonist morphine, MMP-2200 maintained a significantly lower number of drug infusions. To begin investigating potential molecular mechanisms for the reduced side effect profile of MMP-2200, we also examined βarrestin2 (βarr2) recruitment and chronic MMP-2200 induced cAMP tolerance and super-activation at the human delta and mu receptors in vitro. MMP-2200 efficaciously recruited βarr2 to both receptors, and induced cAMP tolerance and super-activation equivalent to or greater than morphine at both receptors. The in vivo findings suggest that MMP-2200 may be less reinforcing than morphine but may have some abuse potential. The reduced side effect profile cannot be explained by reduced βarr2 recruitment or reduced cAMP tolerance and superactivation at the monomeric receptors in vitro.

AB - Abstract Previous work in our laboratories provides preclinical evidence that mixed-action delta/mu receptor glycopeptides have equivalent efficacy for treating pain with reduced side effect profiles compared to widely used mu agonist analgesics such as morphine. This study evaluated the rewarding and reinforcing effects of a lead candidate, mixed-action delta/mu agonist MMP-2200, using a conditioned place preference assay as well as a drug self-administration procedure in rats. In place conditioning studies, rats underwent a 2-week conditioning protocol and were then tested for chamber preference. Rats receiving MMP-2200, at previously determined analgesic doses, could not distinguish between the drug and saline-paired chamber, whereas rats receiving the opioid agonist morphine showed a strong preference for the morphine-paired chamber. In self-administration studies, rats were trained to respond for the high efficacy mu opioid receptor agonist fentanyl on an FR5 schedule of reinforcement. Following complete dose-response determinations for fentanyl, a range of doses of MMP-2200 as well as morphine were tested. Relative to the mu agonist morphine, MMP-2200 maintained a significantly lower number of drug infusions. To begin investigating potential molecular mechanisms for the reduced side effect profile of MMP-2200, we also examined βarrestin2 (βarr2) recruitment and chronic MMP-2200 induced cAMP tolerance and super-activation at the human delta and mu receptors in vitro. MMP-2200 efficaciously recruited βarr2 to both receptors, and induced cAMP tolerance and super-activation equivalent to or greater than morphine at both receptors. The in vivo findings suggest that MMP-2200 may be less reinforcing than morphine but may have some abuse potential. The reduced side effect profile cannot be explained by reduced βarr2 recruitment or reduced cAMP tolerance and superactivation at the monomeric receptors in vitro.

KW - Barrestin2

KW - cAMP

KW - Conditioned place preference

KW - Delta opioid receptor (DOR)

KW - Drug self-administration

KW - Rats

UR - http://www.scopus.com/inward/record.url?scp=84925141063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925141063&partnerID=8YFLogxK

U2 - 10.1016/j.pbb.2015.02.022

DO - 10.1016/j.pbb.2015.02.022

M3 - Article

AN - SCOPUS:84925141063

VL - 132

SP - 49

EP - 55

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

SN - 0091-3057

M1 - 72144

ER -